Ceftibuten Pregnancy and Breastfeeding Warnings
Ceftibuten is also known as: Cedax
Ceftibuten Pregnancy Warnings
Animal studies have failed to reveal evidence of fetal harm. There are no controlled data in human pregnancy.
US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.
This drug should be used during pregnancy only if clearly needed.
US FDA pregnancy category: B
Ceftibuten Breastfeeding Warnings
Use is considered acceptable; caution is recommended.
Excreted into human milk: Yes (in small amounts)
Comments:
-Low levels in milk are not expected to cause harmful effects in the nursing infant.
-Disruption of infant's gastrointestinal flora (resulting in diarrhea or thrush) reported occasionally with cephalosporins, but such effects have not been adequately evaluated.
-Other cephalosporins have been considered compatible with breastfeeding by the American Academy of Pediatrics.
After a single 200 mg oral dose in 6 women, this drug was undetectable (less than 1 mg/L) at any time up to 24 hours after dosing.
See also
References for pregnancy information
- "Product Information. Cedax (ceftibuten)." Schering-Plough (2001):
- Briggs GG, Freeman RK, Yaffe SJ.. "Drugs in Pregnancy and Lactation." Baltimore, MD: Williams & Wilkins (1998):
References for breastfeeding information
- "Product Information. Cedax (ceftibuten)." Schering-Plough (2001):
- Owens RC, Nightingale CH, Nicolau DP "Ceftibuten: an overview." Pharmacotherapy 17 (1997): 707-20
- Briggs GG, Freeman RK, Yaffe SJ.. "Drugs in Pregnancy and Lactation." Baltimore, MD: Williams & Wilkins (1998):
- United States National Library of Medicine "Toxnet. Toxicology Data Network. http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT" (2013):
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.